Gemcitabine: all 1,575 studies that test it

Page 1 of 16. Open to participants first (193), then studies with results posted, then the rest; newest registration first within each.

• Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System LymphomaNot yet recruitingNCT07888621Phase 2
• Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasRecruitingNCT07883135Phase 2
• A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-InvasiveNot yet recruitingNCT07876817Phase 4
• Histotripsy in Biliary Tract CancerRecruitingNCT07853690Not applicable
• Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialRecruitingNCT07847710Phase 2
• Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract CancerRecruitingNCT07831993Phase 2
• Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic CancerNot yet recruitingNCT07831330Phase 2
• Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.Not yet recruitingNCT07808567Phase 2
• Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBTNot yet recruitingNCT07808216Phase 2
• Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingNCT07805954Phase 3
• Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaRecruitingNCT07780838Phase 2
• Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaNot yet recruitingNCT07774234Phase 2
• Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUCRecruitingNCT07741448Phase 2
• DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic CancerRecruitingNCT07705919Phase 1/2
• A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic CancerRecruitingNCT07701486Phase 1/2
• Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBCRecruitingNCT07693959Phase 3
• Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid TumorsRecruitingNCT07671534Phase 2
• An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract MalignanciesRecruitingNCT07668453Phase 2
• Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic CancerNot yet recruitingNCT07665684Phase 1/2
• A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic CholangiocarcinomaNot yet recruitingNCT07632235Phase 1/2
• Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.Not yet recruitingNCT07616362Phase 2
• A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07599423Phase 2
• Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic CancerRecruitingNCT07575191Phase 1/2
• Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic CholangiocarcinomaRecruitingNCT07570849Phase 2
• Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic NeoplasmsRecruitingNCT07529483Phase 2
• HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.Not yet recruitingNCT07528768Phase 2
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT07491445Phase 3
• IBI343 in Combination Therapy for Advanced Malignant Solid TumorsRecruitingNCT07483554Phase 2
• Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingNCT07475234Phase 1/2
• HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract CancerRecruitingNCT07466238Not applicable
• Low Dose Epcoritamab Plus GemOx in R/R DLBCLRecruitingNCT07451652Phase 2
• Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)RecruitingNCT07447076Phase 2
• Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic CancerRecruitingNCT07436741Phase 3
• Cosiporfin Sodium for Injection Photodynamic TherapyRecruitingNCT07398339Phase 2
• Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract CancerRecruitingNCT07392541Phase 1/2
• Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07365306Phase 2
• Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UCEnrolling by invitationNCT07353294Phase 1
• Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingNCT07332351Phase 2
• HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid TumorsRecruitingNCT07296341Phase 1/2
• Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT07259317Phase 2
• BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaRecruitingNCT07226856Phase 2
• Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 StudyNot yet recruitingNCT07189793Phase 2
• Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder CancerNot yet recruitingNCT07184021Phase 2
• Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal AdenocarcinomaRecruitingNCT07163273Phase 2
• Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLCRecruitingNCT07158489Phase 2
• Tegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaRecruitingNCT07144254Phase 1
• Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer PatientsRecruitingNCT07119996Phase 1
• Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic CancerNot yet recruitingNCT07108504Phase 2
• Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal AdenocarcinomaRecruitingNCT07096362Phase 2
• Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic AdenocarcinomaRecruitingNCT07076212Phase 2
• A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.Not yet recruitingNCT07064863Phase 1/2
• A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07062484Not applicable
• Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial CarcinomaRecruitingNCT07043972Phase 2
• 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDACRecruitingNCT07043270Phase 2
• Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar CholangiocarcinomaRecruitingNCT07030140Phase 2
• PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer TreatmentNot yet recruitingNCT07028424Phase 2
• Chemoablation for Low-Grade Bladder CancerRecruitingNCT07019220Phase 2
• Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract CancerNot yet recruitingNCT07003815Phase 2
• Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG TherapyRecruitingNCT07000084Phase 3
• Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic CholangiocarcinomaRecruitingNCT06956716Phase 1/2
• A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerRecruitingNCT06953999Phase 3
• QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic CancerRecruitingNCT06951997Phase 2
• Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial CarcinomaNot yet recruitingNCT06927128Phase 2
• Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.RecruitingNCT06897644Phase 3
• Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.Not yet recruitingNCT06888674Phase 1/2
• Metastatic Nasopharyngeal CarcinomaRecruitingNCT06886347Phase 1
• HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic CholangiocarcinomaRecruitingNCT06858735Phase 2
• A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingNCT06855225Phase 2
• Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNot yet recruitingNCT06829823Phase 2
• DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.RecruitingNCT06820255Phase 4
• Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruitingNCT06806033Phase 2
• Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT06790602Phase 2
• Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic CancerRecruitingNCT06789679Phase 2
• Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic CholangiocarcinomaRecruitingNCT06721286Phase 2
• Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid CancerNot yet recruitingNCT06713057Phase 2
• A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerRecruitingNCT06710288Phase 2
• Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingNCT06708858Phase 2
• In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE TrialRecruitingNCT06704191Phase 1/2
• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBCRecruitingNCT06663137Phase 2
• Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)Not yet recruitingNCT06621095Phase 2
• A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract CancersRecruitingNCT06611345Not applicable
• A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCCRecruitingNCT06597565Phase 2
• Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder CancerRecruitingNCT06591650Phase 2
• LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic PatientsRecruitingNCT06576635Not applicable
• Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic CancerRecruitingNCT06576115Phase 2
• Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCANot yet recruitingNCT06569225Phase 2
• CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract CancersRecruitingNCT06548412Phase 1/2
• Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract CancerRecruitingNCT06546969Phase 1
• Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder CancerRecruitingNCT06488222Phase 2
• Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelRecruitingNCT06483555Phase 1/2
• AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDACRecruitingNCT06472037Phase 2
• A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal CancerRecruitingNCT06457503Phase 4
• Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic CancerRecruitingNCT06454383Phase 1
• Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsNot yet recruitingNCT06446388Phase 2
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingNCT06445062Phase 1/2
• Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic CancerRecruitingNCT06423326Phase 2
• The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential TherapyRecruitingNCT06388720Phase 2
• A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingNCT06377566Phase 2
• Newly Emerging Immunotherapy for Pancreatic Cancer TreatmentNot yet recruitingNCT06370754Phase 1/2

← Gemcitabine overview